Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation
This study has been completed.
Study NCT00481819   Information provided by Astellas Pharma Inc
First Received: May 31, 2007   Last Updated: March 10, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Kidney Transplantation
Interventions listed in this trial
FK506MR
Prograf
Mycophenolate Mofetil
Methylprednisolone
Prednisolone
Additional drug interventions recognized in this trial
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Mycophenolic Acid
Prednisolone acetate
Tacrolimus
More general drug interventions related to this trial
Anti-Inflammatory Agents
Antibiotics, Antineoplastic
Antiemetics
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents
Enzyme Inhibitors
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
Astellas Pharma Inc


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services